Athira Pharma Q2 net loss narrows to $7.0M; cash burn slows; ATH-1105 Phase 1 data support ALS development

LeonaBio, Inc.

2025-Q2 EPS reported -$0.41

Net loss of $7.0M ($0.18/sh) vs $26.9M ($0.70) in Q2 2024, driven by lower R&D and G&A spend.
Cash, equivalents and investments $29.8M as of June 30, 2025, down from $51.3M at Dec 31, 2024.
R&D expenses fell to $3.7M from $22.2M; G&A to $3.6M from $5.9M, reflecting cost reduction after LIFT-AD failure.
Phase 1 trial of ATH-1105 (ALS) showed favorable safety, dose-proportional PK, and CNS penetration; preparation for future ALS trial ongoing.
Company continues to explore strategic alternatives with Cantor Fitzgerald; fosgonimeton development paused.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.